News | News By Subject | News by Disease News By Date | Search News

Thrombocytopenia News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Geron Corporation (GERN) Tanks As FDA Halts Development Of Blood Disorder Drug     3/13/2014
CytoPharm and Amarillo Biosciences (AMAR) Announce Positive HCV Study Results: Oral Interferon Found to Reverse Thrombocytopenia; Reduced Relapse Rate Seen in Patients With Mild Fibrosis     6/15/2012
Exelixis, Inc. (EXEL) Reports Positive Preliminary Phase 2 Cabozantinib Data in Patients With Hepatocellular Carcinoma     1/23/2012
Amgen (AMGN)'s Pivotal Phase 3 Romiplostim Study in Splenectomized Patients Meets Primary Endpoints     12/10/2007
MGI PHARMA, INC. (MOGN) Buys Rights To AkaRx, Inc.'s Blood-Cell Disorder Drug: Upfront Payments of Up to $45 Million     8/29/2007
FDA Approves CSL Behring's Rhophylac(R) for the Treatment of Immune Thrombocytopenic Purpura (ITP)     4/2/2007
Baxter Healthcare Corporation (BAX) Assumes Marketing And Distribution Rights For Cangene Corporation's WinRho SDF In The U.S.     3/29/2005
Alexion Pharmaceuticals (ALXN) And XOMA (XOMA) Form Collaboration     12/18/2003
Puget Sound Blood Center Release: Gene That May Provide Link To Bleeding Disorders Discovered     12/2/2003

News from Around the Web

Press Releases
CTI BioPharma Announces First Patient Enrolled In Phase II Trial Of Pacritinib In Patients With Myelofibrosis Who Have Thrombocytopenia And Who Have Been Previously Treated With Ruxolitinib     8/1/2017
CTI BioPharma Announces EMA Validation Of Pacritinib Marketing Authorization Application For Patients With Myelofibrosis Who Have Thrombocytopenia     7/14/2017
FDA Accepts Rigel (RIGL)'s New Drug Application For TAVALISSE (Fostamatinib Disodium) For The Treatment Of Chronic ITP     6/19/2017
Rigel (RIGL) Submits New Drug Application To FDA For Fostamatinib In Chronic ITP     4/18/2017
Shire (SHPG) Receives FDA Fast Track Designation For Recombinant ADAMTS13 (SHP655) For Treatment Of Hereditary Thrombotic Thrombocytopenic Purpura     3/22/2017
FDA Approves Bio Products Laboratory's Gammaplex 10% For Treatment Of Primary Immunodeficiency And Chronic Immune Thrombocytopenic Purpura     2/7/2017
Rigel (RIGL) Release: Fostamatinib Study Results Continue To Trend Positive     1/30/2017
Galena Biopharma  (GALE) Stocks Jump After FDA Meeting, Blood Cancer Therapy GALE-401 to Enter Phase III     12/28/2016
CTI BioPharma Release: PERSIST-2 Phase 3 Study Of Pacritinib Versus Best Available Therapy Shows Encouraging Clinical Activity In High-Risk Patients With Advanced Myelofibrosis In Late-Breaking Session At American Society of Hematology Annual Meeting     12/6/2016
Baxalta (BXLT) Reports Positive Phase 1 Results For BAX 930, Investigational Recombinant ADAMTS13 To Treat Hereditary Thrombotic Thrombocytopenic Purpura (hTTP)     5/25/2016
Xencor Reports Complete Data Results From XmAb7195 Phase 1a Trial Showing Rapid Reduction Of Serum IgE In High IgE Atopic Subjects At American Thoracic Society 2016 International Conference     5/19/2016
Protalex, Inc. (PRTX) Receives Positive Interim Review From Independent Safety Monitoring Committee In Its European Phase Ib Study Of PRTX-100 To Treat Immune Thrombocytopenia     5/2/2016
Amgen (AMGN) Release: Nplate (Romiplostim) Study In The Lancet Shows Significant Increase In Durable Platelet Response Among Children With Immune Thrombocytopenia     4/20/2016
New Patent Issued To Cantex Pharmaceuticals For Its Lead Product Candidate In The Treatment Of Thrombocytopenia And Neutropenia     3/2/2016
Protalex, Inc. (PRTX) Receives Positive Interim Review From Independent Safety Monitoring Committee In Its U.S. Phase I/II Study Of PRTX-100 For Immune Thrombocytopenia     2/29/2016